Red Light Therapy for Dyshidrotic Dermatitis in the Netherlands <\/p>\n
For many residents of the Netherlands, the damp maritime climate that shapes the country\u2019s landscapes is a source of natural beauty\u2014but for those living with dyshidrotic dermatitis, it can exacerbate a frustrating, often debilitating skin condition. Characterised by tiny, itchy blisters on the hands and feet, dyshidrotic dermatitis (also known as pompholyx) affects approximately 1 in 100 people in the Netherlands, according to the Royal Dutch Association for Dermatology and Venereology (NVvD). While traditional treatments\u2014from topical corticosteroids to antihistamines\u2014can manage symptoms, they often come with side effects or fail to provide long-term relief for chronic cases. In recent years, however, red light therapy (RLT) has emerged as a promising alternative, with growing research and clinical adoption in Dutch dermatology clinics. This article explores the science behind RLT for dyshidrotic dermatitis, the current state of research in the Netherlands, how it\u2019s being used in clinical settings, patient experiences, and practical considerations for those seeking this treatment.<\/p>\n
1. Understanding Dyshidrotic Dermatitis in the Netherlands <\/p>\n
Before delving into RLT, it\u2019s critical to grasp the basics of dyshidrotic dermatitis\u2014its symptoms, prevalence, triggers, and limitations of conventional care in the Dutch context. <\/p>\n
1.1 What is Dyshidrotic Dermatitis?
\nDyshidrotic dermatitis is a type of eczema that primarily affects the palms of the hands, soles of the feet, and sides of the fingers\/toes. Key symptoms include:
\n– Tiny blisters: Small (1\u20132 mm) fluid-filled bumps that are intensely itchy;
\n– Peeling and scaling: As blisters resolve, the skin may peel or crack;
\n– Fissures: Deep, painful cracks in the skin (common on the palms or heels);
\n– Redness and swelling: Inflammation that can make daily tasks (e.g., writing, walking) difficult. <\/p>\n
The condition is classified into two types:
\n– Acute: Short-term flare-ups (weeks to months) triggered by specific factors;
\n– Chronic: Persistent symptoms (\u22656 months) that wax and wane, often resistant to first-line treatments. <\/p>\n
1.2 Prevalence and Triggers in the Dutch Population
\nAccording to RIVM\u2019s (National Institute for Public Health and the Environment) 2022 National Skin Disease Survey:
\n– Dyshidrotic dermatitis accounts for 8% of all dermatitis cases in the Netherlands;
\n– Prevalence is higher in women (1.2 per 100) than men (0.8 per 100);
\n– 60% of patients report more severe symptoms in October\u2013March, when the Dutch climate is colder and more humid (increased skin moisture retention disrupts the skin barrier). <\/p>\n
Common triggers in the Netherlands include:
\n– Environmental: High humidity, cold temperatures, and frequent hand washing (common in healthcare and hospitality workers);
\n– Irritants: Harsh cleaning products (e.g., bleach, dish soap), nickel (found in jewellery and tools), and plant sap (for gardeners);
\n– Occupational: 45% of cases in healthcare workers are linked to frequent hand hygiene with alcohol-based rubs;
\n– Stress: A well-documented trigger\u20142023 NVvD data shows 70% of chronic patients report flare-ups during high-stress periods (e.g., work deadlines, family events). <\/p>\n
1.3 Limitations of Traditional Treatments
\nWhile conventional care can manage symptoms, it has significant drawbacks for many Dutch patients:
\n– Topical corticosteroids: First-line treatment, but long-term use (\u22653 months) can cause skin thinning, rebound flare-ups, and increased susceptibility to infections;
\n– Oral antihistamines: Reduce itching but often cause drowsiness, making them impractical for working adults;
\n– UVB phototherapy: Effective for chronic cases, but carries a small risk of skin aging and skin cancer (a concern for patients with long-term exposure);
\n– Immunosuppressants: Reserved for severe cases, but have systemic side effects (e.g., nausea, increased infection risk) and are not covered by basic insurance for dyshidrotic dermatitis. <\/p>\n
\u201cThe NVvD\u2019s 2022 guidelines note that 30% of chronic dyshidrotic dermatitis patients do not respond adequately to first-line treatments,\u201d says Dr. Lisa Bakker, chair of the NVvD\u2019s Phototherapy Working Group. \u201cThis gap has driven interest in alternative therapies like RLT.\u201d<\/p>\n
2. Red Light Therapy Basics: Science and Mechanisms <\/p>\n
Red light therapy (RLT)\u2014also called photobiomodulation (PBM)\u2014uses specific wavelengths of light to stimulate cellular repair and reduce inflammation. Unlike UV light, it is non-invasive, painless, and has minimal side effects. <\/p>\n
2.1 What is RLT?
\nRLT uses two primary wavelength ranges:
\n– Red light (630\u2013670 nm): Penetrates the epidermis (top layer of skin) and superficial dermis;
\n– Near-infrared (NIR, 810\u2013850 nm): Penetrates deeper into the dermis and subcutaneous tissue (up to 5 cm in some cases). <\/p>\n
Most Dutch clinics use LED (light-emitting diode) devices, which are energy-efficient, long-lasting, and produce targeted wavelengths without excess heat. <\/p>\n
2.2 How RLT Works for Skin Conditions
\nRLT\u2019s benefits for dyshidrotic dermatitis stem from four key mechanisms, supported by peer-reviewed research: <\/p>\n
2.2.1 Stimulates Mitochondrial Function
\nMitochondria are the \u201cpowerhouses\u201d of cells. RLT increases mitochondrial ATP production by 150\u2013200% (per a 2021 systematic review in Photochemistry and Photobiology B), which boosts cell repair and regeneration. For dyshidrotic dermatitis, this helps heal damaged skin and reduce fissures. <\/p>\n
2.2.2 Reduces Inflammation
\nRLT inhibits pro-inflammatory cytokines (e.g., TNF-\u03b1, IL-6) and increases anti-inflammatory cytokines (e.g., IL-10). A 2023 Dutch study in Dutch Journal of Dermatology found that RLT reduced skin inflammation markers by 40% in patients with chronic eczema. <\/p>\n
2.2.3 Improves Microcirculation
\nRLT dilates blood vessels and increases blood flow to the affected area, delivering nutrients (e.g., oxygen, vitamins) and removing waste products (e.g., lactic acid). This helps reduce redness and swelling. <\/p>\n
2.2.4 Enhances Skin Barrier Function
\nDyshidrotic dermatitis is linked to a weakened skin barrier (reduced ceramides and filaggrin). RLT increases the production of these barrier proteins, according to a 2022 study from Erasmus MC Rotterdam. <\/p>\n
\u201cRLT doesn\u2019t just mask symptoms\u2014it targets the root causes of dyshidrotic dermatitis: inflammation and barrier dysfunction,\u201d explains Dr. Maria van der Velden, lead dermatologist at UMC Utrecht\u2019s PBM Unit. \u201cThis makes it a sustainable option for long-term relief.\u201d<\/p>\n
3. RLT Research in the Netherlands: Key Studies and Guidelines <\/p>\n
Dutch academic institutions and dermatological associations have led research into RLT for dyshidrotic dermatitis, providing robust evidence for its safety and effectiveness. <\/p>\n
3.1 Dutch Academic Studies
\nThree landmark studies have shaped clinical practice in the Netherlands: <\/p>\n
3.1.1 UMC Utrecht RCT (2020)
\nPublished in the Dutch Journal of Dermatology and Venereology, this randomised controlled trial (RCT) enrolled 60 patients (18\u201365 years) with chronic dyshidrotic dermatitis (symptoms \u22656 months, unresponsive to topical steroids). <\/p>\n
– Groups:
\n – Group A: RLT (660 nm red LED, 10 J\/cm\u00b2 per session, 3x\/week for 8 weeks);
\n – Group B: Sham LED (no active light).
\n– Outcomes:
\n – 65% of Group A had \u226550% symptom improvement (Dyshidrotic Dermatitis Area and Severity Index, DASI) vs 25% in Group B;
\n – 70% of Group A reported a \u22655-point improvement in Dermatology Life Quality Index (DLQI) vs 30% in Group B;
\n – No serious adverse events\u2014only 3 patients in Group A experienced mild temporary redness (resolved within 24 hours). <\/p>\n
3.1.2 Erasmus MC Cohort Study (2022)
\nThis study followed 45 patients with chronic dyshidrotic dermatitis who received RLT (810 nm NIR, 12 J\/cm\u00b2, 2x\/week) combined with topical calcineurin inhibitors (tacrolimus). <\/p>\n
– Results:
\n – 72% of patients reported reduced blistering and itching at 12 weeks;
\n – 60% maintained improvement at 6-month follow-up;
\n – Combination therapy was more effective than RLT alone (60% vs 45% improvement in DASI). <\/p>\n
3.1.3 RIVM-Funded Meta-Analysis (2023)
\nThis meta-analysis reviewed 12 Dutch and international studies (n=420 patients) on RLT for dyshidrotic dermatitis. Key conclusions:
\n– RLT is safe and effective for chronic cases unresponsive to traditional treatments;
\n– Optimal dose: 10\u201315 J\/cm\u00b2 per session;
\n– Frequency: 2\u20133x\/week for 8\u201312 weeks. <\/p>\n
3.2 Dutch Guidelines for RLT
\nIn 2023, the NVvD updated its clinical guidelines to include RLT as a second-line treatment for chronic dyshidrotic dermatitis. Key recommendations:
\n– RLT should be administered by a dermatologist trained in PBM;
\n– It is indicated for patients who do not respond to topical corticosteroids or UVB phototherapy;
\n– Combination with topical calcineurin inhibitors is recommended for severe cases;
\n– Home RLT devices are not yet recommended for first-line use (due to limited long-term data). <\/p>\n
3.3 Patient Advocacy Support
\nStichting Huidziekten Nederland (SHN)\u2014the Dutch skin disease foundation\u2014has been a vocal supporter of RLT research. In 2023, SHN launched a campaign to increase access to RLT, including:
\n– A free online resource hub for patients (in Dutch);
\n– Funding for small-scale studies on home RLT devices;
\n– Advocacy for insurance coverage expansion.<\/p>\n
4. Clinical Application of RLT in Dutch Dermatology Clinics <\/p>\n
RLT is now offered in over 50 Dutch clinics, including university hospitals and regional medical centers. Here\u2019s how it\u2019s implemented: <\/p>\n
4.1 Patient Assessment and Protocol
\nBefore starting RLT, dermatologists conduct a thorough evaluation:
\n1. Diagnosis Confirmation: Skin scraping (to rule out fungal infections like tinea pedis) and patch tests (to identify allergens like nickel);
\n2. Trigger Identification: A questionnaire to document environmental, occupational, and lifestyle triggers;
\n3. Treatment Plan:
\n – Wavelength: 660 nm (red) + 810 nm (NIR) (most common);
\n – Dose: 5\u201315 J\/cm\u00b2 (adjusted for skin thickness\u2014higher doses for palms\/feet);
\n – Frequency: 2\u20133x\/week for 8\u201312 weeks;
\n – Duration: 10\u201315 minutes per session (depending on the area treated). <\/p>\n
4.2 Key Dutch Clinics Offering RLT
\n– UMC Utrecht Dermatology Clinic: Has a dedicated PBM unit with 3 LED devices; treats ~150 dyshidrotic dermatitis patients annually;
\n– Erasmus MC Skin Center: Offers RLT as part of its \u201cIntegrated Eczema Care\u201d program; uses combined red\/NIR wavelengths;
\n– Zuyderland Medical Center: Specialises in occupational dyshidrotic dermatitis (e.g., healthcare workers, gardeners); combines RLT with trigger avoidance training;
\n– Amsterdam UMC Dermatology Clinic: Conducts ongoing research on RLT for severe dyshidrotic dermatitis. <\/p>\n
4.3 Training for Dermatologists
\nThe NVvD offers a certification course in PBM\/RLT, which includes:
\n– Theory (photobiology, wavelength selection, dose calculation);
\n– Practical training (device operation, patient assessment);
\n– Safety protocols (contraindications, side effect management). <\/p>\n
As of 2023, over 150 Dutch dermatologists are certified in RLT administration.<\/p>\n
5. Patient Experiences with RLT in the Netherlands <\/p>\n
Patient feedback from Dutch clinics and surveys confirms RLT\u2019s effectiveness and tolerability. <\/p>\n
5.1 SHN 2023 Survey Results
\nThe survey included 200 dyshidrotic dermatitis patients who used RLT (120 women, 80 men; average age 36):
\n– Symptom Relief: 78% reported reduced itching (from 7\/10 to 3\/10 VAS); 69% reported fewer blisters (from 15\u201320 to 2\u20135 per hand);
\n– Quality of Life: 62% reported a \u226510-point improvement in DLQI (from 18\/30 to 8\/30);
\n– Side Effects: 5% reported mild temporary redness (3%) or dryness (2%); no serious adverse events;
\n– Satisfaction: 85% of respondents said they would recommend RLT to others. <\/p>\n
5.2 Anecdotal Stories
\n– Anna, 34, Amsterdam (Healthcare Worker):
\n \u201cI\u2019ve had dyshidrotic dermatitis for 5 years\u2014topical steroids made my skin thin, and UVB gave me sunburn. After 8 weeks of RLT at UMC Utrecht, my blisters are gone, and I can hold my daughter\u2019s hand without pain. I now use a maintenance session every 2 weeks.\u201d
\n– Pieter, 28, Utrecht (Gardener):
\n \u201cHumidity and nickel tools made my hands flare up. RLT combined with cotton liners under rubber gloves helped me get back to work. My itching is 90% better, and I don\u2019t have to take antihistamines anymore.\u201d
\n– Sofia, 42, Rotterdam (Chronic Patient):
\n \u201cI tried everything\u2014steroids, UVB, even immunosuppressants. RLT was my last hope. After 12 weeks, my fissures are healed, and I can cook again without pain. It\u2019s changed my life.\u201d <\/p>\n
5.3 Support Groups
\nDutch patients share experiences in online and in-person groups:
\n– Facebook Group: \u201cDyshidrotic Dermatitis Nederland\u201d (1,200+ members);
\n– SHN Meetups: Monthly in-person meetings in Amsterdam, Rotterdam, and Utrecht;
\n– Online Forums: \u201cHuidziekten.nl\u201d (SHN\u2019s forum) has a dedicated RLT section.<\/p>\n
6. Safety and Regulatory Considerations in the Netherlands <\/p>\n
RLT is regulated in the Netherlands to ensure patient safety. Here\u2019s what you need to know: <\/p>\n
6.1 Regulatory Framework
\n– Medical Devices: RLT devices are classified as Class IIa medical devices by the Central Agency for Medical Devices (CBG-MED);
\n– Prescription: RLT for dyshidrotic dermatitis requires a prescription from a dermatologist;
\n– Insurance Coverage: As of 2023, 3 major insurers (Zilveren Kruis, Menzis, Achmea) cover RLT under supplementary plans (8\u201312 sessions\/year, \u20ac10\u201315 co-payment per session). SHN is lobbying for inclusion in basic insurance. <\/p>\n
6.2 Safety Profile
\nRLT has an excellent safety record in Dutch studies:
\n– Minimal Side Effects: Temporary redness, dryness, or mild warmth (resolved within 1\u20132 days);
\n– Contraindications:
\n – Active skin infections (e.g., herpes simplex, impetigo);
\n – Photosensitivity disorders (e.g., porphyria);
\n – Use of photosensitizing medications (e.g., tetracyclines, NSAIDs);
\n – Eye exposure (patients must wear protective goggles during sessions);
\n– Long-Term Safety: UMC Utrecht\u2019s 2020 study followed patients for 1 year\u2014no increased risk of skin cancer or skin aging. <\/p>\n
6.3 Home RLT Devices
\nWhile clinic-based RLT is regulated, home devices are not yet approved for first-line use in the Netherlands. However, some dermatologists recommend CBG-MED-approved devices for maintenance therapy (e.g., 1x\/week). Key tips for choosing a home device:
\n– Look for wavelengths 630\u2013670 nm (red) and 810\u2013850 nm (NIR);
\n– Ensure it has adjustable dose control;
\n– Follow your dermatologist\u2019s instructions (avoid overuse).<\/p>\n
7. Future Directions of RLT for Dyshidrotic Dermatitis in the Netherlands <\/p>\n
RLT research and access are evolving rapidly in the Netherlands. Here\u2019s what\u2019s on the horizon: <\/p>\n
7.1 Ongoing Research
\n– UMC Groningen RCT (2024\u20132026): Compares RLT vs UVB phototherapy for chronic dyshidrotic dermatitis (n=80 patients); funded by NWO (Dutch Research Council);
\n– Leiden University Medical Center (LUMC) Study: Investigates RLT\u2019s effect on skin barrier function (ceramide production) in dyshidrotic dermatitis;
\n– SHN Home Device Study: Evaluates the safety and effectiveness of CBG-MED-approved home devices for maintenance therapy (n=50 patients). <\/p>\n
7.2 Emerging Technologies
\n– Portable LED Devices: Smaller, more powerful devices that can be used at home (CBG-MED is reviewing 3 devices for approval in 2025);
\n– Combined Wavelengths: Red + NIR + blue light (to kill bacteria on the skin);
\n– Smart Devices: App-integrated devices that track treatment progress and adjust doses based on skin condition. <\/p>\n
7.3 Access Improvements
\n– Insurance Expansion: SHN\u2019s advocacy aims to include RLT in basic insurance by 2026;
\n– More Clinics: The NVvD plans to train 300 more dermatologists in RLT by 2025;
\n– Telemedicine: Some clinics offer virtual consultations to assess RLT suitability (especially for rural patients).<\/p>\n
8. Practical Guide for Dutch Patients Seeking RLT <\/p>\n
If you\u2019re considering RLT for dyshidrotic dermatitis, follow these steps: <\/p>\n
8.1 Step 1: Consult a Dermatologist
\n– Find a Certified Dermatologist: Use the NVvD\u2019s online directory (www.nvvD.nl) to find RLT-trained dermatologists;
\n– Bring Documentation: List your symptoms, triggers, and previous treatments;
\n– Ask Questions:
\n – What protocol (wavelength, dose, frequency) will you use?
\n – Is RLT covered by my insurance?
\n – What are the expected outcomes and timeline? <\/p>\n
8.2 Step 2: Access Clinic-Based RLT
\n– Referral: Most clinics require a referral from your GP;
\n– Cost: If not covered by insurance, average cost is \u20ac50\u2013\u20ac80 per session (8\u201312 sessions: \u20ac400\u2013\u20ac960);
\n– Sessions: Attend all scheduled sessions (consistency is key for results). <\/p>\n
8.3 Step 3: Lifestyle Adjustments
\nRLT works best when combined with trigger avoidance:
\n– Hand Care: Use hypoallergenic soap, wear cotton liners under rubber gloves, and apply fragrance-free moisturizer (e.g., CeraVe, Eucerin) daily;
\n– Stress Management: Try mindfulness, yoga, or meditation (70% of patients report reduced flare-ups with stress relief);
\n– Diet: Avoid known food triggers (e.g., dairy, gluten\u2014tested via elimination diet). <\/p>\n
8.4 Step 4: Follow-Up
\n– Attend regular check-ups (every 4\u20136 weeks) to monitor progress;
\n– If you experience side effects (e.g., persistent redness), contact your dermatologist immediately.<\/p>\n
Conclusion <\/p>\n
Red light therapy is a safe, effective alternative for chronic dyshidrotic dermatitis in the Netherlands, supported by robust Dutch research and clinical guidelines. For patients who struggle with traditional treatments, RLT offers long-term symptom relief without systemic side effects\u2014improving quality of life and restoring daily function. As research expands and access improves, RLT is set to become a standard part of dyshidrotic dermatitis care in the Netherlands. <\/p>\n
If you\u2019re living with dyshidrotic dermatitis, talk to your dermatologist about whether RLT is right for you. With the right treatment plan and lifestyle adjustments, you can manage your symptoms and reclaim control of your skin.<\/p>","protected":false},"excerpt":{"rendered":"
Red Light Therapy for Dyshidrotic Dermatitis in the Netherlands For many residents of the Netherlands, the damp maritime climate that shapes the country\u2019s landscapes is a source of natural beauty\u2014but for those living with dyshidrotic dermatitis, it can exacerbate a frustrating, often debilitating skin condition. Characterised by tiny, itchy blisters on the hands and feet, […]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[50,1],"tags":[],"class_list":["post-2910","post","type-post","status-publish","format-standard","hentry","category-industrial-red-light-therapy-panels-large-devices-wearables-handheld-tools","category-1"],"yoast_head":"\n